MET and breast cancer: Recent studies conducted on different tumor entities, such as breast cancer and HCC, indicated that MET and FAK are involved in the signaling crosstalk occurring in tumor cells [66,67], representing a mechanism of “oncogene switching”, which is adopted by cancer cells to counteract the inhibition of specific receptor tyrosine kinases [68].